|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
1997
|
|
gptkbp:ATCCode
|
L02BG04
|
|
gptkbp:brand
|
gptkb:letrozole
|
|
gptkbp:CASNumber
|
gptkb:112809-51-5
|
|
gptkbp:chemicalFormula
|
C17H11N5
|
|
gptkbp:contraindication
|
pregnancy
premenopausal women
|
|
gptkbp:drugClass
|
aromatase inhibitor
|
|
gptkbp:eliminationHalfLife
|
2 days
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericName
|
gptkb:letrozole
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Femara
|
|
gptkbp:indication
|
metastatic breast cancer
adjuvant therapy
hormone receptor positive breast cancer
|
|
gptkbp:KEGGID
|
D08123
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
inhibits aromatase enzyme
|
|
gptkbp:MedlinePlusID
|
a698016
|
|
gptkbp:MeSH_ID
|
D019821
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL960
3902
DB01006
|
|
gptkbp:reduces
|
estrogen production
|
|
gptkbp:RxNormID
|
31208
|
|
gptkbp:sideEffect
|
nausea
fatigue
joint pain
hot flashes
|
|
gptkbp:UNII
|
T6X3OCM3UY
|
|
gptkbp:usedFor
|
gptkb:cancer
postmenopausal women
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|